Ondansetron treatment in Tourette's disorder: A 3-week, randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 66, Issue 4, 2005, Pages 499-503

  Toren, Paz ^a,b,e   Weizman, Abraham ^b,c   Ratner, Sharon ^a   Cohen, Donald ^d   Laor, Nathaniel ^a,b,d  

^a TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIDINE; GUANFACINE; HALOPERIDOL; ONDANSETRON; PERGOLIDE MESILATE; PIMOZIDE; PLACEBO; RISPERIDONE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TIC; TOURETTE SYNDROME GLOBAL SCALE; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE; YALE GLOBAL TIC SEVERITY SCALE;

EID: 17844384538     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0413     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Chase TN, Friedhoff AJ, Cohen DJ, eds. Tourette Syndrome: Genetics, Neurobiology, and Treatment. New York, NY: Raven Press; 1992
3. Robertson MM. Tourette syndrome: associated conditions and the complexities of treatment. Brain 2000;123:425-462
4. Shapiro AK, Shapiro E. Treatment of tic disorders with haloperidol. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, NY: Wiley, 1988:267-281
5. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996;57:29-31
6. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60:1130-1135
7. Budman CL, Gayer A, Lesser M, et al. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 2001;62:290-294
8. Conner DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001;62:967-974
9. Gothelf D, Apter A, Reidman J, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003;110:545-560
10. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41:337-343
11. Labellarte MG, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003;42:642-650
12. Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144:673-675
13. Sandor P. Pharmacological management of tics in patients with TS. J Psychosom Res 2003;55:41-48
14. Rammes G, Eisensamer B, Ferrari U, et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry 2004;9:846-858
15. Wilde MI, Markham A. Ondansetron: a review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773-794
16. Toren P, Laor N, Cohen DJ, et al. Ondansetron treatment in patients with Tourette's syndrome. Int Clin Psychopharmacol 1999;14:373-376
17. Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000;355:792-797
18. Bier JC, Dethy S, Hildebrand J, et al. Effects of the oral form of ondansetron on cerebellar dysfunction: a multi-center double-blind study. J Neurol 2003;250:693-697
19. Sirota P, Mosheva T, Shabtai H, et al. Treating tardive dyskinesia with ondansetron [letter]. J Clin Psychopharmacol 2001;21:355-356
20. Harcherik DF, Leckman JF, Detlor J, et al. A new instrument for clinical studies of Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1984;23:153-160
21. Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorder severity. In: Cohen DJ, Brunn RD, Leckman JF, eds. Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, NY: John Wiley; 1988:55-78
22. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-573
23. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
24. Scahill L, Riddle MA, Hardin MT, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and variability. J Am Acad Child Adolesc Psychiatry 1997;36:844-852
25. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
26. Sirota P, Mosheva T, Shabtay H, et al. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry 2000;157:287-289
27. Sirota P, Korczyn AD. Reply to possible duplicate publication [letter]. J Clin Psychopharmacol 2002;22:233
28. Lee SH, Oh DY, Jung SC, et al. Neuroleptic drugs alter the dopamine transporter-mediated uptake and release of dopamine: a possible mechanism for drug-induced tardive dyskinesia. Pharmacol Res 1997;35:447-450
29. Melamed E, Friedberg G, Zoldan J. Psychosis: impact on the patient and family. Neurology 1999;52:S14-S16
30. Costall B, Naylor RJ, Tyers MB. The psychopharmacology of 5-HT3 receptors. Pharmacol Ther 1990;47:181-202
31. Naidu PS, Kulkarni SK. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists. Eur J Pharmacol 2001;420:113-117
32. Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64:1025-1030
33. Culy CR, Bhana N, Plosker GL. Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs 2001;3:441-479
34. Ramsook C, Sahagun-Carreon I, Kozinetz CA, et al. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med 2002;39:397-403